Article

Cautious Addition of Targeted Therapy to PD-1 Inhibitors after Initial Progression of BRAF Mutant Metastatic Melanoma on Checkpoint Inhibitor Therapy

2021-04-05

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Virtually all metastatic melanoma patients who progress after initial treatment with PD-1 or CTLA-4 directed antibodies will die of their disease. Salvage options are urgently needed. It is theoretically attractive to combine immunotherapy with targeted agents in progressing patients with BRAF mutation positive melanoma, but the toxicity of combined treatment ha...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1b38bcfd-5627-592a-8b6b-c2afb746a5a4
DOI: 10.21203/rs.3.rs-386981/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cautious Addition of Targeted Therapy to PD-1 Inhibitors after Initial Progression of BRAF Mutant Metastatic Melanoma on Checkpoint Inhibitor TherapyDOI 10.21203/rs.3.rs-386981/v1Read

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.Semantic proximity Read

Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma.Semantic proximity Read

Management of V600E and V600K BRAF-Mutant Melanoma.Semantic proximity Read

Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.Semantic proximity Read

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.Semantic proximity Read

Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.Semantic proximity Read

Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st-line BRAF-targeted therapy.Semantic proximity Read

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.Semantic proximity Read

Reduction of soluble PD-L1 by plasma exchange and radiation therapy in patients with refractory melanoma re-sensitizes to immunotherapy.Semantic proximity Read

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.Semantic proximity Read

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.Semantic proximity Read

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.Semantic proximity Read